论文信息 - A matched couple

A matched couple

Small-molecule kinase inhibitors targeting oncogenic signaling pathways have been explored as cancer therapeutic agents due to their strong anti-tumor activity and manageable toxicity. Accumulating evidence shows that many kinase inhibitors also profoundly modulate immune cell functions, suggesting they may be promising candidates for combination with immunotherapeutic agents for the improved treatment of cancer.

J. Weiss | Q. Jiang | R. Wiltrout

[1] S. Liang,et al. Recombinant VP1, an Akt Inhibitor, Suppresses Progression of Hepatocellular Carcinoma by Inducing Apoptosis and Modulation of CCL2 Production , 2011, PloS one.

[2] J. Weiss,et al. mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment. , 2011, Cancer research.

[3] M. Boutros,et al. Drosophila Ras/MAPK signalling regulates innate immune responses in immune and intestinal stem cells , 2011, The EMBO journal.

[4] P. Shrikant,et al. Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines , 2011, British Journal of Cancer.

[5] D. Schadendorf,et al. Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma , 2009, Clinical Cancer Research.

[6] A. Thomson,et al. Immunoregulatory functions of mTOR inhibition , 2009, Nature Reviews Immunology.

[7] Tae Woo Kim,et al. Activation of Akt as a mechanism for tumor immune evasion. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[8] D. Heitjan,et al. CCL2 blockade augments cancer immunotherapy. , 2010, Cancer research.